Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 11/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.56 |
| ▸ | CCR6 | P51684 | 2/20 | 0.56 |
| ▸ | FAAH | O00519 | 4/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5078820 | 0.95 | MGLL (0.62) | MGLLHSP90AA1CCR6FAAHNSD2 | |
| SCHEMBL8641616 | 0.83 | MGLL (0.70) | MGLLHSP90AA1CCR6FAAHNSD2 | |
| SCHEMBL19067079 | 0.80 | TSHR (0.44) | MGLLHSP90AA1CCR6FAAHNSD2 | |
| SCHEMBL19067074 | 0.80 | MGLL (0.61) | MGLLHSP90AA1CCR6FAAHG6PD | |
| SCHEMBL30645229 | 0.78 | HPN (0.60) | MGLLHSP90AA1CCR6FAAHNSD2 | |
| SCHEMBL26667209 | 0.78 | HPN (0.60) | MGLLHSP90AA1CCR6FAAHNSD2 | |
| SCHEMBL962950 | 0.77 | MGLL (1.00) | MGLLHSP90AA1CCR6FAAHNPSR1 | |
| SCHEMBL2847212 | 0.77 | MGLL (1.00) | MGLLHSP90AA1FAAHPKMALDH1A1 | |
| SCHEMBL11666213 | 0.77 | MGLL (0.48) | MGLLHSP90AA1CCR6FAAHNSD2 | |
| SCHEMBL25586084 | 0.77 | MGLL (0.48) | MGLLHSP90AA1CCR6FAAHNSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56071006-A | — | — | None | — | — | JP | disclosed |
| CN-113717948-B | Hybridoma cell strain secreting anti-sclerotinia monoclonal antibody and application thereof | 江南大学 | 2023-09-15 | — | — | CN | disclosed |
| CN-113717948-B | Hybridoma cell strain secreting anti-sclerotinia monoclonal antibody and application thereof | 江南大学 | 2023-09-15 | — | — | CN | disclosed |
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2023-02-23 | — | — | US | disclosed |
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB, LLC | 2023-02-23 | — | — | US | disclosed |
| US-20220064195-A1 | SYNTHETIC I2 IMIDAZOLINE RECEPTOR LIGANDS FOR PREVENTION OR TREATMENT OF HUMAN BRAIN DISORDERS | UNIVERSITAT DE LES ILLES BALEARS (ES) | 2022-03-03 | — | — | US | disclosed |
| EP-3917516-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | Flatley Discovery Lab, LLC (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3897838-A1 | <SUP2/>? <SUB2/>?2?SYNTHETIC IIMIDAZOLINE RECEPTOR LIGANDS FOR PREVENTION OR TREATMENT OF HUMAN BRAIN DISORDERS | Universitat de Barcelona (ES) | 2021-10-27 | — | — | EP | disclosed |
| EP-3154941-B1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2021-01-20 | — | — | EP | disclosed |
| EP-3154941-B1 | SMALL MOLECULE LFA-1 INHIBITORS | ALLOCYTE PHARMACEUTICALS AG (CH) | 2021-01-20 | — | — | EP | disclosed |
| JP-S5671006-A | INDUSTRIAL MILDEWCIDE | IHARA CHEM IND CO LTD | 1981-06-13 | — | — | JP | disclosed |
| US-4111879-A | RESIN AND AN N-ARYL-MALEIMIDE | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1978-09-05 | — | — | US | disclosed |
| US-4082849-A | FUNGICIDES, BACTERICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-04-04 | — | — | US | disclosed |
| US-4081267-A | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-03-28 | — | — | US | disclosed |
| US-4054668-A | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-10-18 | — | — | US | disclosed |
| US-4033752-A | FUNGICIDES, HERBICIDES | SUMITOMO CHEMICAL COMPANY, LTD. (JA) | 1977-07-05 | — | — | US | disclosed |
| US-4025651-A | N-substituted-aminoacetamides used as fungicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-05-24 | — | — | US | disclosed |
| US-4009278-A | Antimicrobial composition and method containing N-(3,5-dihalophenyl)-imide compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1977-02-22 | — | — | US | disclosed |
| US-3993771-A | FUNGICIDES; ALPHA-BENZYLIDINE-GAMMA-BUTYROLACTONE | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-11-23 | — | — | US | disclosed |
| US-3966789-A | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064195-A1 | SYNTHETIC I2 IMIDAZOLINE RECEPTOR LIGANDS FOR PREVENTION OR TREATMENT OF HUMAN BRAIN DISORDERS | CHRM1, GPR3, CHRM3 | MGLL 3253/4885HSP90AA1 3670/4885CCR6 3504/4885 |
| US-20230055237-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, MPST, CRAT | MGLL 2475/4885HSP90AA1 2760/4885CCR6 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.